Abstract
1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have